Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.58 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.45 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14217277 | 0.94 | GLP1R (0.57) | GLP1RNOD1C3AR1EPHX2MEN1 | |
| SCHEMBL14477502 | 0.94 | GLP1R (0.57) | GLP1RNOD1C3AR1EPHX2MEN1 | |
| SCHEMBL15871524 | 0.91 | GLP1R (0.62) | GLP1RNOD1C3AR1 | |
| SCHEMBL14217286 | 0.91 | GLP1R (0.53) | GLP1RNOD1C3AR1EPHX2MEN1 | |
| SCHEMBL21172251 | 0.91 | GLP1R (0.62) | GLP1RNOD1C3AR1EPHX2MEN1 | |
| SCHEMBL14217386 | 0.90 | GLP1R (0.53) | GLP1RNOD1C3AR1EPHX2MEN1 | |
| SCHEMBL15871510 | 0.90 | GLP1R (0.58) | GLP1RNOD1C3AR1 | |
| SCHEMBL16472579 | 0.89 | GLP1R (0.52) | GLP1RNOD1C3AR1MEN1KMT2A | |
| SCHEMBL19069582 | 0.88 | GLP1R (0.56) | GLP1RC3AR1FOLH1 | |
| SCHEMBL19286722 | 0.87 | GLP1R (0.56) | GLP1RNOD1C3AR1EPHX2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695226-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-20160058879-A1 | Growth Hormone Compound Formulation | NOVO NORDISK HEALTHCARE AG (CH) | 2016-03-03 | — | — | US | disclosed |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-17 | — | — | US | disclosed |
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | GHRHR, SHBG, GHSR | GLP1R 99/4885NOD1 4656/4885C3AR1 1465/4885 |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | GLP1R 101/4885NOD1 4722/4885C3AR1 1771/4885 |
| US-20160058879-A1 | Growth Hormone Compound Formulation | GHRHR, GHSR, GHITM | GLP1R 39/4885NOD1 4810/4885C3AR1 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.